InMed Competitors

INM Stock  USD 5.26  0.11  2.14%   
InMed Pharmaceuticals competes with Quoin Pharmaceuticals, Allarity Therapeutics, Virax Biolabs, Biodexa Pharmaceticals, and LMF Acquisition; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing InMed Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of InMed Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out InMed Pharmaceuticals Correlation with its peers.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of InMed Pharmaceuticals competition on your existing holdings.
  
At this time, InMed Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 6.45, while Return On Tangible Assets are likely to drop (4.61). At this time, InMed Pharmaceuticals' Tangible Asset Value is very stable compared to the past year. As of the 15th of December 2024, Intangibles To Total Assets is likely to grow to 0.40, while Net Tangible Assets are likely to drop about 9.1 M.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.265.2112.11
Details
Intrinsic
Valuation
LowRealHigh
0.234.5411.44
Details
Naive
Forecast
LowNextHigh
0.115.4812.38
Details

InMed Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between InMed Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of InMed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of InMed Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SONNICU
ZVSAICU
SONNZVSA
BDRXALLR
ICUALLR
SONNALLR
  
High negative correlations   
KRBPQNRX
ICUQNRX
ALLRQNRX
SONNQNRX
ZVSAQNRX
REVBQNRX

Risk-Adjusted Indicators

There is a big difference between InMed Stock performing well and InMed Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze InMed Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
QNRX  5.60  0.36  0.06  0.55  5.35 
 9.21 
 74.46 
ALLR  3.82 (1.50) 0.00 (1.22) 0.00 
 5.80 
 41.48 
KRBP  6.00 (0.26) 0.00 (0.17) 0.00 
 12.04 
 65.24 
VRAX  5.27 (0.41) 0.00  0.82  0.00 
 9.65 
 61.28 
BDRX  6.68 (0.89) 0.00 (0.27) 0.00 
 13.30 
 97.78 
ICU  4.09 (1.42) 0.00 (0.98) 0.00 
 7.17 
 27.64 
VIRI  5.85 (0.23) 0.00  0.26  0.00 
 12.46 
 50.54 
ZVSA  3.70 (0.55) 0.00  0.27  0.00 
 7.55 
 78.93 
SONN  5.34 (1.61) 0.00  12.13  0.00 
 13.38 
 37.58 
REVB  4.26 (1.13) 0.00 (0.66) 0.00 
 8.97 
 73.15 

Cross Equities Net Income Analysis

Compare InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
QNRX15.3 M15.3 M15.3 M15.3 M15.3 M15.3 M15.3 M10.2 M15.3 M(1.6 M)(1.8 M)(8.5 M)(9.3 M)(8.7 M)(8.3 M)
ALLR(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(14.4 M)(5.1 M)(26.6 M)(16.1 M)(11.9 M)(12.5 M)
VRAX(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(801.1 K)(651 K)(1.7 M)(5.5 M)(6.7 M)(6.4 M)
BDRX(4 M)(4 M)(4 M)(4.1 M)(8.8 M)(10.1 M)(6.2 M)(11.7 M)(10.4 M)(9.1 M)(22.2 M)(5.5 M)(7.7 M)(7.1 M)(7.4 M)
ICU(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(3.3 M)(4.6 M)(23 M)(26.2 M)(24.9 M)
ZVSA(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(8.9 M)(759.1 M)(98.3 M)(103.2 M)
SONN(1 M)(1 M)(6 M)(6.4 M)(6.4 M)(12.1 M)(6.8 M)(6.9 M)(6.9 M)(5 M)(25 M)(29.8 M)(18.8 M)(5 M)(5.3 M)
REVB4.5 M4.5 M4.5 M4.5 M4.5 M6.2 M8.8 M16.3 M27.6 M(3.6 K)(136.4 K)(12 M)(10.8 M)(120.3 K)(114.2 K)
PALI(3.1 M)(12.5 M)(10.1 M)(19.8 M)(22.6 M)(20.9 M)(21.1 M)(15.7 M)(4.9 M)(8.4 M)(10.6 M)(27.3 M)(12.8 M)(12.3 M)(12.9 M)
DRUG(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(485.9 K)(8.5 M)(15.2 M)(7.4 M)(6.6 M)(7 M)
TNXP(21.1 K)(3.5 M)(9.4 M)(10.9 M)(27.6 M)(48.1 M)(38.8 M)(21.1 M)(26.1 M)(28.4 M)(50.4 M)(92.2 M)(115 M)(116.7 M)(110.8 M)
IMMX(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(972.8 K)(1.1 M)(24.4 M)(8.2 M)(15.4 M)(16.2 M)
PHIO(10.2 M)(10.2 M)(12.9 M)(20.9 M)(8.8 M)(10.2 M)(9 M)(12.5 M)(7.4 M)(8.8 M)(8.8 M)(13.2 M)(11.3 M)(10.8 M)(11.4 M)
ATNF(3.1 K)(3.1 K)(3.1 K)(3.1 K)(3.1 K)(3.1 K)(3.1 K)123.8 K(14.5 M)(25.4 M)(10.9 M)(10.9 M)(38.7 M)(19.9 M)(20.9 M)
NBY(977 K)(5.1 M)(7 M)(16 M)(15.2 M)(19 M)(13.2 M)(7.4 M)(6.5 M)(10.5 M)(11 M)(6.6 M)(16.3 M)(9.6 M)(10.1 M)
GOVX36.7 M(2.3 M)(2.1 M)(2.3 M)(2.7 M)(2.7 M)(3.3 M)(2.2 M)(2.6 M)(2.4 M)(2.9 M)(18.5 M)(14 M)(26 M)(24.7 M)

InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in InMed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of InMed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

InMed Pharmaceuticals Competitive Analysis

The better you understand InMed Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, InMed Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across InMed Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
INM QNRX ALLR KRBP VRAX BDRX ICU VIRI ZVSA SONN
 2.14 
 5.26 
InMed
 9.59 
 0.66 
Quoin
 0.97 
 1.02 
Allarity
 2.55 
 2.68 
Kiromic
 2.48 
 1.57 
Virax
 5.19 
 4.20 
Biodexa
 5.29 
 1.99 
LMF
 0.00 
 3.95 
Virios
 2.78 
 1.05 
ZyVersa
 2.26 
 1.81 
Sonnet
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

InMed Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of InMed Pharmaceuticals Competition

InMed Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by InMed Pharmaceuticals in relation to its competition. InMed Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of InMed Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact InMed Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to InMed Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your InMed Pharmaceuticals position

In addition to having InMed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Exotic Funds Thematic Idea Now

Exotic Funds
Exotic Funds Theme
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out InMed Pharmaceuticals Correlation with its peers.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.